Business Context and Reporting Period
This Form 6-K filing covers the month of October 2025 for I-Mab (intending to change its name to NovaBridge Biosciences). The Company announced a strategic transformation to operate as a biotechnology platform company utilizing specialized subsidiary entities. Key corporate actions include a planned name change subject to shareholder approval on October 24, 2025, and an intention to pursue a dual primary listing on the Hong Kong Stock Exchange (HKEX).
Key Financial Metrics and Transactions
The filing details specific capital transactions and licensing agreements rather than standard periodic financial statements (revenue, profit, or cash flow).
- Visara Series A Financing: The Company agreed to purchase 35 million shares of Series A preferred stock in its subsidiary, Visara, Inc., for approximately $37 million. Affiliate AffaMed subscribed for approximately 16.2 million shares.
- Licensing Upfront Payments:
- $5 million upfront payment to AffaMed for the assignment of rights to VIS-101 (AM712/ASKG712).
- $7 million upfront payment to AskGene Pharma for an exclusive license to develop VIS-101 in specified Asian territories.
- Expense Reimbursement: Agreement to reimburse AskGene up to RMB 24 million for Phase 2a study and toxicology study expenses.
- Liquidity and Debt: The filing text does not provide a clear value for total cash, cash equivalents, or outstanding debt as of the reporting date.
Material Changes and Strategic Shifts
The Company is executing a material shift in its business model and leadership:
- Business Model: Transitioning from a traditional biotech structure to a platform model with separate subsidiaries for focused asset development to enhance risk management.
- Asset Acquisition: Secured rights to VIS-101, a bifunctional biologic targeting VEGF-A and ANG2 for wet AMD and DME, through a combination of equity subscription and licensing.
- Leadership Change: Mr. Kyler Lei was appointed Chief Financial Officer effective October 16, 2025, replacing Mr. Joseph Skelton, who will remain as an advisor.
- Capital Markets: Initiated plans for a dual primary listing on the HKEX Main Board.
Outlook, Risks, and Contingencies
Management commentary highlights the strategic intent to advance high-value assets through partnerships. The filing includes significant forward-looking statements regarding the anticipated benefits of the new strategy, the success of the HKEX listing, and the clinical development of VIS-101 and givastomig.
Key Risks and Contingencies:
- Regulatory and Listing Approval: The HKEX dual listing is subject to market conditions, regulatory approvals, and corporate approvals; completion is not assured.
- Closing Conditions: The Visara Series A Financing and related asset assignments are contingent upon the satisfaction or waiver of customary closing conditions.
- Clinical Uncertainty: Risks include the ability to demonstrate safety and efficacy of drug candidates, regulatory approval timelines, and commercial success.
- Funding: The Company relies on its ability to obtain additional funding for operations and development.
Investor Verification Checklist
- Confirm the outcome of the Extraordinary General Meeting (EGM) on October 24, 2025, regarding the name change to NovaBridge Biosciences.
- Verify the closing of the Visara Series A Financing and the receipt of the $37 million investment.
- Monitor the status of the HKEX dual primary listing application and any regulatory feedback.
- Review the definitive terms of the VIS-101 license agreement and the timeline for the Phase 2a study initiation.
- Assess the Company's updated cash runway following the $12 million in immediate upfront payments ($5M to AffaMed, $7M to AskGene) and the $37M capital raise.